Technical Analysis for BYSI - BeyondSpring, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Crossed Above 50 DMA | Bullish | -3.94% | |
Expansion Pivot Buy Setup | Bullish Swing Setup | -3.94% | |
Pocket Pivot | Bullish Swing Setup | -3.94% | |
Wide Bands | Range Expansion | -3.94% | |
Above Upper BB | Strength | -3.94% |
Alert | Time |
---|---|
Possible NR7 | about 11 hours ago |
Possible Inside Day | about 12 hours ago |
60 Minute Opening Range Breakout | about 14 hours ago |
Down 5% | about 14 hours ago |
Down 3% | about 14 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 04/18/2024
BeyondSpring, Inc. Description
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.0 |
52 Week Low | 0.6534 |
Average Volume | 257,311 |
200-Day Moving Average | 1.35 |
50-Day Moving Average | 2.55 |
20-Day Moving Average | 2.12 |
10-Day Moving Average | 2.24 |
Average True Range | 0.26 |
RSI (14) | 53.92 |
ADX | 19.48 |
+DI | 27.22 |
-DI | 22.41 |
Chandelier Exit (Long, 3 ATRs) | 1.89 |
Chandelier Exit (Short, 3 ATRs) | 2.51 |
Upper Bollinger Bands | 2.56 |
Lower Bollinger Band | 1.69 |
Percent B (%b) | 0.86 |
BandWidth | 41.11 |
MACD Line | -0.03 |
MACD Signal Line | -0.08 |
MACD Histogram | 0.0532 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.72 | ||||
Resistance 3 (R3) | 2.75 | 2.67 | 2.68 | ||
Resistance 2 (R2) | 2.67 | 2.60 | 2.66 | 2.66 | |
Resistance 1 (R1) | 2.56 | 2.56 | 2.52 | 2.53 | 2.65 |
Pivot Point | 2.48 | 2.48 | 2.47 | 2.47 | 2.48 |
Support 1 (S1) | 2.37 | 2.41 | 2.33 | 2.35 | 2.23 |
Support 2 (S2) | 2.29 | 2.37 | 2.28 | 2.22 | |
Support 3 (S3) | 2.18 | 2.29 | 2.20 | ||
Support 4 (S4) | 2.16 |